BioNTech’s Founder Exit and Factory Shrinkage Mask a €17 Billion Bet on Oncology
Published on 06/20/2026 at 18:23 | Redaktion boerse-global.de
The Mainz-based biotech is caught in a curious tug-of-war. Its management is aggressively buying back shares, its cancer pipeline is piling up late-stage data, and its coffers hold €17.2 billion in cash. Yet the stock languishes at €78.70, a quarter below its 52-week high, as investors grapple with a founder departure and a sweeping reduction in manufacturing footprint. The latest twist: archrival Moderna wants to pick up the pieces.
Moderna chief Stéphane Bancel has confirmed his interest in acquiring the German and Singapore sites BioNTech plans to mothball. Last month, BioNTech announced the closure of three German factories and one in Singapore, cutting roughly 1,900 jobs by the end of 2027. Bancel told the Handelsblatt that taking over the facilities would be cheaper than building new ones, and he is open to retaining the affected workforce — provided a suitable agreement with the German government can be reached. No binding contract exists yet.
The factory pullback comes alongside a parallel financial operation that began on June 8: a share buyback programme authorised in early May, allowing the repurchase of up to 24.9 million shares — worth as much as $1 billion — through an independent bank, with the mandate running until May 2027. Management is effectively betting that the stock’s post-founders-departure discount is unwarranted.
That discount stems primarily from the March 10 announcement that co-founders Ugur Sahin and Ă–zlem TĂĽreci will leave their executive posts by the end of 2026 to start a next-generation mRNA company. BioNTech will receive a minority stake and milestone payments from the new venture, with a binding contract expected this month. The shares plunged more than 20% on the news and have never fully recovered, shedding roughly 13% over the past twelve months. Analysts at Leerink Partners called the departure a logical maturation step, arguing the company is on track for multiple product launches by 2030.
Should investors sell immediately? Or is it worth buying BioNTech?
The market’s fixation on the leadership vacuum has largely ignored the operational progress. BioNTech is running 15 phase 3 oncology studies this year, including six that began in 2025. Recent data from the ASCO meeting in late May showed durable anti-tumour activity for Gotistobart in ovarian cancer and encouraging results for Pumitamig in lung cancer. UBS responded by upgrading the stock to Buy with a $135 price target, explicitly citing growing confidence in the oncology pipeline.
The financial underpinnings are solid but the income statement is still bleeding red. In the first quarter, BioNTech reported a net loss of roughly €532 million on revenue of just €118 million, while research spending consumed €557 million. Management aims to cut half a billion euros in costs by 2029 — a rational move as the company transitions from pandemic-era revenue toward commercial oncology sales.
Technically, the share is neutral. The RSI sits at 50.4, and the price is about 3% below its 50-day moving average of €81.16, while the 52-week low of €68.35 provides a floor. The analyst consensus target of €106.50 implies upside of about 35% — a gap that several sell-side firms consider a buying opportunity rather than a value trap.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Two near-term catalysts loom. On June 30, management will deliver a strategic briefing, followed by full second-quarter results on August 4. Yet the most powerful lever remains in the hands of the supervisory board: naming a new CEO. Until that is resolved, the stock is likely to trade in a range — coiled, but waiting for a trigger that costs nothing to pull.
Ad
BioNTech Stock: New Analysis - 20 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
